Suppr超能文献

变构抑制剂 8-苯胺-1-萘磺酸(ANS)与细胞周期蛋白依赖性激酶 2 的变构抑制剂之间的协同作用。

Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.

机构信息

Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.

Department of Pharmacology, School of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, United States.

出版信息

ACS Chem Biol. 2020 Jul 17;15(7):1759-1764. doi: 10.1021/acschembio.0c00169. Epub 2020 May 20.

Abstract

While kinases have been attractive targets to combat many diseases, including cancer, selective kinase inhibition has been challenging, because of the high degree of structural homology in the active site, where many kinase inhibitors bind. We have previously discovered that 8-anilino-1-naphthalene sulfonic acid (ANS) binds an allosteric pocket in cyclin-dependent kinase 2 (Cdk2). Here, we detail the positive cooperativity between ANS and orthosteric Cdk2 inhibitors dinaciclib and roscovitine, which increase the affinity of ANS toward Cdk2 5-fold to 10-fold, and the relatively noncooperative effects of ATP. We observe these effects using a fluorescent binding assay and heteronuclear single quantum correlation nuclear magnetic resonance (HSQC NMR), where we noticed a shift from fast exchange to slow exchange upon ANS titration in the presence of roscovitine but not with an ATP mimic. The discovery of cooperative relationships between orthosteric and allosteric kinase inhibitors could further the development of selective kinase inhibitors in general.

摘要

虽然激酶一直是对抗包括癌症在内的许多疾病的有吸引力的靶点,但由于活性位点的高度结构同源性,许多激酶抑制剂结合于此,选择性激酶抑制一直具有挑战性。我们之前发现 8-苯胺-1-萘磺酸(ANS)结合细胞周期蛋白依赖性激酶 2(Cdk2)的变构口袋。在这里,我们详细描述了 ANS 与构象选择性 Cdk2 抑制剂 dinaciclib 和 roscovitine 之间的正协同作用,这将 ANS 与 Cdk2 的亲和力提高了 5 到 10 倍,而 ATP 的作用则相对非协同。我们使用荧光结合测定法和异核单量子相关核磁共振(HSQC NMR)观察到这些效应,其中我们注意到在 roscovitine 存在下,ANS 滴定时从快速交换转变为缓慢交换,但与 ATP 模拟物没有这种情况。构象选择性和变构性激酶抑制剂之间协同关系的发现可以进一步推动一般选择性激酶抑制剂的发展。

相似文献

3
A novel approach to the discovery of small-molecule ligands of CDK2.一种发现 CDK2 小分子配体的新方法。
Chembiochem. 2012 Sep 24;13(14):2128-36. doi: 10.1002/cbic.201200316. Epub 2012 Aug 14.
5
Discovery of a potential allosteric ligand binding site in CDK2.发现 CDK2 中的一个潜在别构配体结合位点。
ACS Chem Biol. 2011 May 20;6(5):492-501. doi: 10.1021/cb100410m. Epub 2011 Feb 22.

引用本文的文献

2
Allosteric regulation and inhibition of protein kinases.别构调节和蛋白激酶抑制。
Biochem Soc Trans. 2023 Feb 27;51(1):373-385. doi: 10.1042/BST20220940.

本文引用的文献

2
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.单靶点和双靶点突变型 EGFR 的变构抑制剂
Cancer Discov. 2019 Jul;9(7):926-943. doi: 10.1158/2159-8290.CD-18-0903. Epub 2019 May 15.
9
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.联合维莫非尼和考比替尼治疗 BRAF 突变型黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验